Sanara MedTech Inc.
For the period ended Dec 31, 2025. Filed Mar 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 24, 2026
SMTI$31.66-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 · 2024 | |||
| Cash flows from operating activities: | |||
| Net loss | $(37,568,047) | $(9,911,898) | |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||
| Depreciation and amortization | 3,945,965 | 4,923,224 | |
| Asset impairment charges | 28,313,527 | - | |
| Gain on disposal of property and equipment | (9,674) | - | |
| Credit loss expense | 509,233 | 624,448 | |
| Inventory obsolescence | 582,046 | 521,757 | |
| Share-based compensation | 5,154,761 | 4,436,048 | |
| Noncash lease expense | 525,372 | 547,297 | |
| Share of losses from equity method investments | 952,466 | 90,007 | |
| Back-end fee | 780,312 | 358,086 | |
| Paid-in-kind interest | 2,199,613 | 838,965 | |
| Accretion of finance liabilities | 148,179 | 210,931 | |
| Amortization and write-off of debt issuance costs | 279,905 | 209,499 | |
| Change in fair value of earnout liabilities | - | (1,938,451) | |
| Accrued interest income | - | (21,978) | |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | (114,690) | (4,508,958) | |
| Accounts receivable – related parties | 40,566 | (32,166) | |
| Inventory, net | (1,777,762) | 1,442,744 | |
| Prepaid and other assets | 123,515 | (515,496) | |
| Accounts payable | 813,999 | (424,318) | |
| Accounts payable – related parties | (5,913) | (46,891) | |
| Accrued royalties and expenses | 292,195 | 574,189 | |
| Accrued bonuses and commissions | 2,127,966 | 3,102,069 | |
| Operating lease liabilities | (526,905) | (502,892) | |
| Net cash provided by (used in) operating activities | 6,786,629 | (23,784) | |
| Cash flows from investing activities: | |||
| Purchases of property and equipment | (4,625,650) | (205,848) | |
| Proceeds from disposal of property and equipment | 60,000 | - | |
| Purchases of intangible assets | (23,452) | (23,452) | |
| Investment in equity securities | (8,262,642) | (5,302,952) | |
| Convertible loan receivable | - | (1,079,391) | |
| CarePICS Acquisition | (2,122,146) | - | |
| Net cash used in investing activities | (14,973,890) | (6,611,643) | |
| Cash flows from financing activities: | |||
| Loan proceeds, net of debt issuance costs of $228,183 in 2025 and $1,160,740 in 2024 | 12,021,817 | 29,339,260 | |
| Pay off line of credit | - | (9,750,000) | |
| Pay off debt assumed in CarePICS Acquisition | (1,650,000) | - | |
| Equity offering net expenses | - | (75,000) | |
| Net settlement of equity-based awards | (546,994) | (125,205) | |
| Cash payment of finance and earnout liabilities | (937,000) | (2,022,549) | |
| Net cash provided by financing activities | 8,887,823 | 17,366,506 | |
| Net increase in cash | 700,562 | 10,731,079 | |
| Cash, beginning of period | 15,878,295 | 5,147,216 | |
| Cash, end of period | $16,578,857 | $15,878,295 | |
| Cash paid during the period for: | |||
| Interest | $3,351,791 | $1,580,984 | |
| Taxes | 48,792 | 40,586 | |
| Supplemental noncash investing and financing activities: | |||
| Non-monetary exchange to acquire intangible assets | $2,084,278 | $ | - |
| Conversion of note receivable into equity method investment | 1,101,478 | - | |
| Earnout liability generated by CarePICS Acquisition | 1,355,603 | - | |
| Right of use assets obtained in exchange for lease obligations | 1,153,099 | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.